Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791*
- 15 July 2008
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 69 (2), 259-263
- https://doi.org/10.1111/j.1365-2265.2008.03215.x
Abstract
Hereditary medullary thyroid carcinoma (MTC) is caused by germ-line mutations in the RET proto-oncogene. Our study addresses the difference in development of MTC between rare mutations in RET codons 790, 791 and 804.We evaluated tumour stage, calcitonin levels, biochemical cure rates and associated endocrinopathies in 153 German/Austrian patients with RET 790 (n = 47), 791 (n = 56) and 804 mutations (n = 50), divided into index- and screening groups.Age at diagnosis in index-patients did not differ significantly among the three codon groups (medians of 57, 61 and 53 years). Tumour stage at diagnosis was significantly less advanced with codon 791 (n = 22) than 790 (n = 16) and 804 (n = 16) mutations (P = 0.001). In screening patients, age at diagnosis did not differ significantly among the three groups (medians 19, 24 and 32 years). Tumour stage at diagnosis was also significantly less advanced with codon 791 (n = 34) than 790 (n = 31) and 804 (n = 34) (P = 0.032). Preoperative basal calcitonin levels were significantly lower in codon 791 carriers compared to codon 790 carriers, and cure rates were significantly higher in both index (75%vs. 31%; P = 0.03) and screening patients (100%vs. 75%; P = 0.015). Additional endocrinopathies were observed only with codon 791 carriers (four pheochromocytomas and two hyperparathyroidism).There is a significant difference in MTC development with less extensive C-cell disease, higher cure rate and more frequent additional endocrinopathies in carriers of RET codon 791 mutations compared with carriers of codons 790 and 804 mutations. This information should be considered when age of prophylactic thyroidectomy is discussed.Keywords
This publication has 17 references indexed in Scilit:
- RET Proto-Oncogene in Sardinia: V804M Is the Most Frequent Mutation and May Be Associated with FMTC/MEN-2A PhenotypeThyroid®, 2007
- Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotypeActa Endocrinologica, 2006
- Primary Hyperparathyroidism as the Leading Symptom in a Patient with a Y791F RET MutationThyroid®, 2005
- Early Diagnosis and Curative Therapy of Medullary Thyroid Carcinoma by Routine Measurement of Serum Calcitonin in Patients with Thyroid DisordersThyroid®, 2005
- Frequency of RET Proto-Oncogene Mutations in Patients with Normal and with Moderately Elevated Pentagastrin-Stimulated Serum Concentrations of CalcitoninThyroid®, 2004
- Early Malignant Progression of Hereditary Medullary Thyroid CancerNew England Journal of Medicine, 2003
- Hereditäres medulläres Schilddrüsenkarzinom - Genotyp - Phänotyp CharakterisierungDeutsche Medizinische Wochenschrift (1946), 2003
- RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?Surgery, 2002
- Various Penetrance of Familial Medullary Thyroid Carcinoma in Patients With RET Protooncogene Codon 790/791 Germline MutationsAnnals of Surgery, 2002
- A New Hot Spot for Mutations in the ret Protooncogene Causing Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2AJournal of Clinical Endocrinology & Metabolism, 1998